Home>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>Taprenepag isopropyl (PF-04217329)

Taprenepag isopropyl (PF-04217329) (Synonyms: PF-04217329)

Catalog No.GC31919

Taprenepag isopropyl (PF-04217329) is a highly selective EP2 receptor agonist.

Products are for research use only. Not for human use. We do not sell to patients.

Taprenepag isopropyl (PF-04217329) Chemical Structure

Cas No.: 1005549-94-9

Size Price Stock Qty
5mg
$72.00
In stock
10mg
$131.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Taprenepag isopropyl is a highly selective EP2 receptor agonist.

Taprenepag isopropyl is a highly selective EP2 receptor agonist. Intraocular pressure (IOP) in the left, vehicle-dosed eye typically remains within the normal range. In the right (Taprenepag isopropyl-dosed) eye, IOP is reduced in all dose groups. In the high-dose group, IOP is reduced to the extent that it cannot be measured (<4mm Hg) on Days 22 and 29. There are no clinical signs or changes in body weight observed with any dose of Taprenepag isopropyl administration, and noocular findings occur for animals in the low-dose group (0.75 mg/day)[1].

[1]. Yanochko GM, et al. Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma. J Ocul Pharmacol Ther. 2014 Jun;30(5):429-39.

Reviews

Review for Taprenepag isopropyl (PF-04217329)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Taprenepag isopropyl (PF-04217329)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.